Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|March 15, 2021

CEPI Plans to Reduce Risk of Future Pandemics and Epidemics with Global Leaders’ Support and a $3.5 Billion Plan

Currently, supporters of the plan include the governments of Germany, Norway, and Ethiopia; Wellcome and the Bill and Melinda Gates Foundation; the World Economic Forum; and WHO, Gavi, and UNICEF.

The Coalition for Epidemic Preparedness Innovations (CEPI) announced on March 10, 2021 that governments and global health organizations have shown their support for CEPI’s $3.5 billion plan to reduce or eliminate the future risk of pandemics and epidemics.

According to a company press release, CEPI plans to dedicate $1 billion of the $3.5 billion toward the research and development of new vaccines aimed at variants of concern. The company also plans to launch a call for proposals at the end of March 2021 that will provide $200 million in funding for an “all-in-one” vaccine that could protect against several strains of coronaviruses, including SARS, MERS-CoV, and SARS-CoV-2.

Additionally, CEPI released a six-point strategy to prepare for the next possible outbreak. Its strategies include:

  • Reducing the risk of a future coronavirus pandemic by improving current vaccines, targeting variants of concern, developing new vaccines, and developing universal vaccines.
  • Developing and completing vaccines for additional known threats, including chikungunya, Lassa fever, Nipah, MERS, Rift Valley fever, and Ebola.
  • Limiting vaccine development timelines to 100 days.
  • Organizing a library of protype vaccines.
  • Creating global networks for lab capacity, assays, and preclinical models for rapid vaccine development.
  • Taking full ownership of low- and middle-income countries’ national health security by conducting epidemiological and clinical studies, supporting technology transfer, and establishing national and regional vaccine manufacturing.

Currently, supporters of the plan include the governments of Germany, Norway, and Ethiopia; Wellcome and the Bill and Melinda Gates Foundation; the World Economic Forum; and the World Health Organization, Gavi, and UNICEF, according to the press release.

“Reducing the risk of future pandemics and epidemics is a critical global issue that will benefit every single human on earth,” said Richard Hatchett, CEO, CEPI, in the press release. “The backing from governments and global health bodies for CEPI’s plan is testament to the importance of this issue, and the unique role that CEPI plays in this global effort. Our five-year plan is ambitious, yet achievable, and we look forward to working with everyone who has backed us so far to protect the world from the devastating impacts of pandemics and epidemics.”

Source: CEPI


Related to this article

The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.